Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company Drug

Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study

Fineline Cube Dec 14, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...

Company Medical Device

Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study

Fineline Cube Dec 14, 2022

China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...

Policy / Regulatory

China’s COVID-19 Vaccination Second Booster Shot Plan Released

Fineline Cube Dec 14, 2022

The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...

Company Drug

ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval

Fineline Cube Dec 14, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...

Company Drug

Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial

Fineline Cube Dec 14, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...

Company Drug

Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting

Fineline Cube Dec 14, 2022

China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...

Company Medical Device

Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation

Fineline Cube Dec 14, 2022

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...

Policy / Regulatory

Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues

Fineline Cube Dec 13, 2022

The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...

Company Deals

Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...

Policy / Regulatory

China’s State Council Boosts Internet Medical Services Amid COVID-19

Fineline Cube Dec 13, 2022

The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...

Company Drug

Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202

Fineline Cube Dec 13, 2022

China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...

Company Drug

Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone

Fineline Cube Dec 13, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...

Company Drug

Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment

Fineline Cube Dec 13, 2022

China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...

Company Deals

Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M

Fineline Cube Dec 13, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100%...

Company Medical Device

Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia

Fineline Cube Dec 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its...

Company Drug

Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting

Fineline Cube Dec 13, 2022

China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...

Company R&D

ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform

Fineline Cube Dec 13, 2022

Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with...

Company Deals

Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...

Company Drug

JW Therapeutics Presents Carteyva Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...

Company Deals

4B Technologies Raises RMB 100M in Pre-Series B Financing Round

Fineline Cube Dec 13, 2022

China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development,...

Posts pagination

1 … 566 567 568 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.